Get the Stockscreener App
0.1121
4.13%
-0.0067
Aditxt Inc stock is traded at $0.1121, with a volume of 182.86M.
It is down -4.13% in the last 24 hours and down -6.64% over the past month.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
See More
Previous Close:
$0.1188
Open:
$0.1195
24h Volume:
182.86M
Relative Volume:
3.43
Market Cap:
$9.37M
Revenue:
$212.10K
Net Income/Loss:
$-40.19M
P/E Ratio:
-0.000021
EPS:
-5313.2836
Net Cash Flow:
$-13.92M
1W Performance:
+62.71%
1M Performance:
-6.64%
6M Performance:
-99.71%
1Y Performance:
-99.92%
1-Day Range:
$0.1009
$0.133
1-Week Range:
$0.0739
$0.158
52-Week Range:
$0.0654
$218.00
Aditxt Inc Stock (ADTX) Company Profile
Name
Aditxt Inc
Sector
Industry
Phone
909-488-0844
Address
737 N. FIFTH STREET, SUITE 200, RICHMOND
Compare ADTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADTX
Aditxt Inc
|
0.1124 | 9.37M | 212.10K | -40.19M | -13.92M | -5,313.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.12 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.03 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.93 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.37 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.25 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aditxt Inc Stock (ADTX) Latest News
Aditxt subsidiary Persanta engages Dominary Securities for IPO - TipRanks
Aditxt Co's Unit Pearsanta Engaged Dominari Securities Llc As Lead Underwriter For Pearsanta's Planned IPO - Marketscreener.com
Aditxt subsidiary Pearsanta prepares for IPO with lead underwriter By Investing.com - Investing.com South Africa
Aditxt, Inc Subsidiary Pearsanta Engages Dominari Securities for its IPO By Investing.com - Investing.com Australia
Aditxt, Inc Subsidiary Pearsanta Engages Dominari Securities for its IPO - Investing.com India
Aditxt subsidiary Pearsanta prepares for IPO with lead underwriter - Investing.com
Can This New DNA Cancer Test Disrupt the $20B Diagnostics Market? Pearsanta Unveils IPO Plans - StockTitan
Microcap Biotech Aditxt Rallies Retail Interest Ahead Of CEO’s Fireside Chat: What’s On Investors’ Radar? - MSN
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
ADTX Stock Earnings: Aditxt Reported Results for Q1 2024 - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why GCL Global Holdings Shares Are Trading Higher By Around 107%; Here Are 20 Stocks Moving Premarket - Benzinga
Aditxt, Inc. (NASDAQ:ADTX) Sees Significant Decline in Short Interest - Defense World
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025 - TradingView
Appili Q3 Earnings: Pipeline Success With $14M Funding, FDA Progress, and Take-Private Deal | APLIF Stock News - StockTitan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
ADTX stock plunges to 52-week low, touches $0.07 By Investing.com - Investing.com South Africa
ADTX stock plunges to 52-week low, touches $0.07 - Investing.com
Inside Aditxt's Pipeline: CEO Reveals Latest on Type 1 Diabetes Treatment and Cancer Detection Program - StockTitan
Metric Deep Dive: Understanding Aditxt Inc (ADTX) Through its Ratios - The Dwinnex
A stock that deserves closer examination: Aditxt Inc (ADTX) - US Post News
Market cap of Aditxt Inc [ADTX] reaches 7.10M – now what? - The DBT News
Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater
Understanding the Risks of Investing in Aditxt Inc (ADTX) - Knox Daily
Aditxt Inc (NASDAQ: ADTX) Could Pass $160 In One Year Stock Forecast - Stocks Register
ADTX’s Market Whiplash: -42.04% YTD Decline, -42.04% Plunge in 30 Days - The InvestChronicle
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Growth in Short Interest - Defense World
Aditx Therapeutics stock hits 52-week low at $0.12 By Investing.com - Investing.com Australia
Aditx Therapeutics stock hits 52-week low at $0.12 - MSN
Aditxt (NASDAQ: ADTX) Board Considers IPO for Subsidiary PearsantaMountain View, CA – January 13, 2025 – Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”) announced today that its Board of Directors has given the green light for exploring the p - Defense World
Aditxt explores IPO for subsidiary Pearsanta in 2025 By Investing.com - Investing.com Canada
Aditxt explores IPO for subsidiary Pearsanta in 2025 - Investing.com India
Aditxt, Inc. Plans IPO for Pearsanta in 2025 - TipRanks
Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform - Quantisnow
Aditx Therapeutics stock hits 52-week low at $0.17 By Investing.com - Investing.com Australia
Aditx Therapeutics stock hits 52-week low at $0.17 - Investing.com
ADTX Stock on the Rise: A Promising Investment - The InvestChronicle
Shares Of Aditxt Inc (NASDAQ: ADTX): Are They Overvalued Compared To Others? - Stocks Register
Aditxt Inc (NASDAQ: ADTX) Inclines 3.78%: This $2.72 million Stock Could Go Down -79900.0% - Stocks Register
Perspective Therapeutics Inc (AMEX: CATX) Could Fell Another -684.31% - Stocks Register
Devon Energy Corp (NYSE: DVN) Stock Forecast: Could Pass $55 In A Year - Stocks Register
No Stopping Energy Transfer LP (NYSE: ET)’s Stock Surged? - Stocks Register
Aditxt, Inc. (NASDAQ:ADTX) Short Interest Down 45.2% in December - Defense World
ADTX stock plunges to 52-week low, touches $0.18 By Investing.com - Investing.com Nigeria
ADTX stock plunges to 52-week low, touches $0.18 - Investing.com
Aditx Therapeutics stock hits 52-week low at $0.31 By Investing.com - Investing.com Canada
Aditx Therapeutics stock hits 52-week low at $0.31 - Investing.com
Aditxt, Inc. (NASDAQ:ADTX) Sees Large Decrease in Short Interest - Defense World
Aditxt Advances ADI-100 Therapy to Human Trials - TipRanks
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Quantisnow
Leslies Inc (LESL) Is Worth A Look Now, Despite -69.79% Loss From High - Stocks Register
Aditxt Inc Stock (ADTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aditxt Inc Stock (ADTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Oct 16 '24 |
Sale |
1.17 |
25,534 |
29,875 |
0 |
0.07%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):